
sep pm et
summari form merger quintil contract research organ im
provid prescript electron health record data
price-to-earnings oper ep
risk assess account market leadership
posit compani well demand see
health care data drug develop howev note
face signific competit withdraw
delay larg drug develop project
oct ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
sep stock trade
look sale januari
adopt revenu recognit
standard new standard
recogn revenu unit
percentag complet basi
standard requir servic revenu
reimburs expens revenu treat
consist present one line
revenu re-cast
revenu would look sale
technolog analyt solut formerli
commerci solut increas
solut rise contract sale
engag servic fall
octob im health quintil
transnat merg deal combin
largest contract research organ
one largest provid data
servic drug health care
ceo quintil tom pike presid
geographically-divers client base
america europ
middl east africa asia pacif
novemb compani chang
name iqvia
recent upgrad recommend
share buy hold
encourag robust new busi
sign aid addit new
client sinc start year invest
technolog help drive innov attract
new client enabl gain market
share view momentum like
carri share trade
forward ep estim
peer attract valu
calcul peer multipl expand
demand industri consolid
solut net new busi
month end june
year ago howev view highli
leverag net debt/ebitda
sale cost save synergi
slowdown outsourc spend
target base
in-line-with-p forward
ep estim see ep aid
stock buy-back program
repurchas billion stock
post-merg current
remain stock buy-back program
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview quintilesim hold inc form octob merger
quintil transnat lead contract research organ im health lead provid
prescript electron health record data combin compani lead integr
inform technolog healthcar servic provid novemb quintilesim chang name
iqvia
quintil provid biopharmaceut develop servic commerci outsourc servic
conduct busi approxim countri quintil offer servic two segment
product develop integr healthcar servic product develop provid servic
expertis enabl biopharmaceut compani outsourc clinic develop process
first-in-man clinic trial post-launch monitor product develop compris clinic
solut servic consult clinic solut servic provid servic necessari develop
biopharmaceut product includ project manag clinic monitor function
conduct multi-sit clinic trial gener phase ii-iv clinic trial support servic
improv clinic trial decision-mak data manag strateg plan design servic
improv decis perform consult provid strategi manag consult
servic base deep life scienc expertis advanc analyt well regulatori complianc
consult servic clinic solut servic enabl conduct coordin multi-sit
clinic trial gener phase ii-iv servic offer includ protocol design feasibl
oper plan site start patient recruit project manag monitor
investig site data patient visit
im oper inform technolog servic compani provid client health care
industri solut measur improv perform world-wide compani
collect health care inform span sale prescript promot data medic claim
electron medic record social media compani data set contain approxim petabyt
data approxim million longitudin anonym patient record record link
time anonym individu across health care set compani presenc
compani serv key health care organ decis maker world-wide span breadth
life scienc compani includ pharmaceut biotechnolog consum health medic devic
manufactur well distributor provid payer govern agenc policymak research
financi commun juli compani oper three busi segment
contract sale medic solut formerli integr engag servic
compani princip inform offer compris nation inform offer approxim
countri provid consist country-level perform metric relat sale pharmaceut
product prescrib trend medic treatment promot activ across multipl channel
includ retail hospit mail order client use product measur rel perform
assess market opportun determin brand compani strategi understand market dynam
product avail rang frequenc weekli annual deliv variou
format includ on-line host pc mobil platform
compani sub-nat offer compris servic approxim countri provid
consist measur sale prescrib activ region zip code individu prescrib
level product use extens major pharmaceut sale organ within
countri depend servic set goal determin resourc measur perform
calcul compens compani onekey refer databas track approxim million
health care profession countri provid view health care practition critic
commerci success market sale initi
compani also provid rang cloud-bas applic associ implement servic
softwar servic saa solut support rang commerci regulatori process includ
compens territori align roster manag call plan complianc report master
data manag solut use health care compani manag optim execut
commerci strategi orchestr manner meet regulatori oblig
competit within technolog analyt solut compani face numer competitor
includ larg corpor certain govern agenc corpor competitor includ cogniz
technolog covanc optuminsight parexel intern among other within
unit competitor includ tradit contract research organ icon plc covanc
parexel syneo pharmaceut product develop
financi trend januari adopt revenu recognit standard
new standard recogn revenu unit percentag complet basi
standard requir servic revenu reimburs expens revenu treat consist
present one line incom statement report revenu re-cast
revenu would first full year combin oper
former quintil transnat im health adjust ep
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
bullish sinc juli technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
life scienc tool servic sub-industri
next month think among
fastest-grow sub-industri within
health care sector see solid fund
privat public sourc help drive
billion increas nation
institut nih fy budget
billion septemb
billion increas fy budget
increas contrast presid
trump call cut nih budget
billion billion fy fy
signific fund academ lab
turn account sale life
scienc tool compani averag
trump propos indic
administr prioriti actual fund
determin congress think
signific bipartisan support nih
believ congress disregard trump propos
cut nih budget nonetheless trump
propos budget creat uncertainti
may result project termin
cloud futur research project
view nih budget rose
billion billion
largest percentag increas sinc
includ billion stimulu fund
american recoveri reinvest act
arra
decemb presid obama sign
centuri cure act law law
provid billion year
nation institut split
go cancer moonshot billion
fund precis medicin initi
billion fund brain
initi support alzheim diseas
overal see mid-singl high-singl digit
sale growth emerg market
china remain robust growth region
grow rate mid-teen help fuel
overal industri growth believ demand
strong begin moder
think research lab suffici
equip current need mani
equip compani also diversifi
product line increas sale
consum typic immun
budget constraint expand
area environment food
safeti agricultur growth
end-market expect robust
pharmaceut research
end-market howev note mani life
scienc compani activ pursu
initi commerci non-academ
govern revenu base
compani provid servic
pharmaceut biotech firm
contract research organ see
solid growth next month
view believ pharmaceut biotech
firm increasingli outsourc servic
think increas effici lower
cost also see increas strateg
 life scienc tool
servic rose vs rise
 composit index year date
juli life scienc tool
servic rose vs rise
base index
five-year market price perform sep
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
et cfra rais recommend share iqvia hold
inc buy hold rais target
line peer forward ep estim
ep vs ahead estim rais
ep estim ep estim
sale rose technolog analyt solut formerli commerci
solut research develop solut rose
servic fell contract sale smallest unit account
sale within latest net new
busi win year-ago period quarterli
basi book-to-bil robust see invest
technolog innov enabl compani win new busi client
ad new custom
encourag new busi win client add believ
keep target price line peer
ep estim ep vs
ahead estim adopt account standard
recogn revenu percentag complet basi requir reimburs
expens servic revenu consist present one line
incom statement sale includ fx benefit rose
commerci solut research develop solut
integr engag iqv smallest unit net new busi
research develop unit last month rose
quarterli basi net new busi win rose book-to-bil
backlog march modest
encourag net new busi sign note leverag
remain high net debt/ebitda /jeffrey loo cfa
et cfra keep hold opinion share ia hold
rais target line peer
ep estim set ep
vs ahead estim pro-forma sale rose
commerci solut research develop solut
integr engag servic fell guid sale
re-cast sale adopt
revenu recogn percentag complet basi
reimburs expens treat consist servic revenu /jeffrey
hold inc keep target
in-lin peer ep estim ep vs
estim sale reflect merger im
rose pro forma basi research develop
solut sale rose commerci solut sale rose slightli
forecast view new busi sign past month
drive backlog solid repurchas billion share
quarter million remain buy-back program
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
